Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pramipexole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 5/20 | 0.97 |
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 0.97 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | HRH2 | P25021 | 2/20 | 0.97 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.97 |
| ▸ | HTR1A | P08908 | 1/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.97 |
| ▸ | HTR1B | P28222 | 1/20 | 0.97 |
| ▸ | HTR2A | P28223 | 1/20 | 0.97 |
| ▸ | HTR7 | P34969 | 1/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.97 |
| ▸ | HRH1 | P35367 | 1/20 | 0.97 |
| ▸ | HTR2B | P41595 | 1/20 | 0.97 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.97 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.97 |
| ▸ | SCN3A | Q9NY46 | 5/20 | 0.55 |
| ▸ | SCN4A | P35499 | 4/20 | 0.55 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pramipexole SCHEMBL939869 | 1.00 | ADRA2A (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Pramipexole SCHEMBL4099920 | 1.00 | ADRA2A (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Pramipexole SCHEMBL42113 | 1.00 | ADRA2A (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Dexpramipexole SCHEMBL910147 | 1.00 | ADRA2A (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Pramipexole SCHEMBL2995942 | 1.00 | ADRA2A (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Pramipexole SCHEMBL4440257 | 1.00 | ADRA2A (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Pramipexole SCHEMBL28716749 | 1.00 | ADRA2A (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Pramipexole SCHEMBL743891 | 0.99 | DRD3 (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Pramipexole SCHEMBL2048695 | 0.99 | DRD3 (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Pramipexole SCHEMBL7106169 | 0.99 | ADRA2A (0.97) | ADRA2ADRD3DRD2DRD4HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 483 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000910-A1 | METHOD FOR TREATING PARKINSON'S DISEASE THROUGH PHOTOSTIMULATION, AND DEVICE USED IN SAID METHOD | TSUBOTA LAB INC (JP) | 2026-01-01 | — | — | US | claimed |
| EP-4537896-A1 | METHOD FOR TREATING PARKINSON'S DISEASE THROUGH PHOTOSTIMULATION, AND DEVICE USED IN SAID METHOD | Juntendo Educational Foundation (JP) | 2025-04-16 | — | — | EP | claimed |
| WO-2025026438-A1 | PRAMIPEXOLE ORAL SOLUBLE FILM COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海云晟研新生物科技有限公司 | 2025-02-06 | — | — | WO | claimed |
| CN-119343168-A | Method for treating parkinson's disease by light stimulation and device used in method | 学校法人顺天堂 | 2025-01-21 | — | — | CN | claimed |
| CN-117462481-A | Promoter for promoting nasal delivery of pharmaceutical ingredients and application thereof | 南京星叶生物科技有限公司 | 2024-01-30 | — | — | CN | claimed |
| WO-2023238956-A1 | METHOD FOR TREATING PARKINSON'S DISEASE THROUGH PHOTOSTIMULATION, AND DEVICE USED IN SAID METHOD | 学校法人順天堂 | 2023-12-14 | — | — | WO | claimed |
| CN-114886874-B | Oral instant film and preparation method thereof | 沈阳信达泰康医药科技有限公司 | 2023-11-17 | — | — | CN | claimed |
| US-11801236-B2 | Pramipexole hydrochloride oral liquid | CHANGZHOU NO.4 PHARMACEUTICAL FACTORY CO. LTD (CN) | 2023-10-31 | — | — | US | claimed |
| CN-112569208-B | Pramipexole dihydrochloride pharmaceutical composition and preparation method thereof | 四川科伦药物研究院有限公司 | 2023-10-31 | — | — | CN | claimed |
| WO-2023078180-A1 | MINI-TABLET, AND PREPARATION METHOD THEREFOR AND FORMULATION THEREOF | 北京微智瑞医药科技有限公司 | 2023-05-11 | — | — | WO | claimed |
| WO-2008052953-A1 | THE USE OF PRAMIPEXOLE OR A SALT THEREOF FOR THE TREATMENT OF PARKINSON'S DISEASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-08 | — | — | WO | claimed |
| EP-1898886-A2 | NOVEL SUSTAINED RELEASE DOSAGE FORM | Rubicon Research Private Limited (IN) | 2008-03-19 | — | — | EP | claimed |
| WO-2008000418-A2 | NEW METHOD FOR SALT PREPARATION | SANDOZ AG (CH) | 2008-01-03 | — | — | WO | claimed |
| WO-2008001204-A2 | TRANSDERMAL COMPOSITIONS OF PRAMIPEXOLE HAVING ENHANCED PERMEATION PROPERTIES | ANTARES PHARMA IPL AG (CH) | 2008-01-03 | — | — | WO | claimed |
| WO-2007075095-A1 | PROCESS FOR THE PREPARATION OF PRAMIPEXOLE BASE AND/OR ITS SALTS | INSTYTUT FARMACEUTYCZNY (PL) | 2007-07-05 | — | — | WO | claimed |
| WO-2007052299-A2 | CONTROLLED RELEASE FORMULATION | RUBICON RESEARCH PVT LTD. (IN) | 2007-05-10 | — | — | WO | claimed |
| WO-2007036952-A2 | NOVEL SUSTAINED RELEASE DOSAGE FORM | RUBICON RESEARCH PVT LTD. (IN) | 2007-04-05 | — | — | WO | claimed |
| WO-2003022252-A2 | COMBINATORIAL TYPE (SEVERAL VEHICLES WITHIN A HOUSING) CONTROLLED RELEASE DRUG DELIVERY DEVICE | INTELLIPHARMACEUTICS CORP. (CA) | 2003-03-20 | — | — | WO | claimed |
| US-20030050620-A1 | Combinatorial type controlled release drug delivery device | ITELLIPHARMACEUTICS CORP. (CA) | 2003-03-13 | — | — | US | claimed |
| US-20010053777-A1 | Drug treatment for restless leg syndrome | BRECHT HANS MICHAEL (DE) | 2001-12-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000910-A1 | METHOD FOR TREATING PARKINSON'S DISEASE THROUGH PHOTOSTIMULATION, AND DEVICE USED IN SAID METHOD | PARK7, SNCA, PMP22 | DRD3 152/4885DRD2 71/4885DRD4 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.